Recent developments include the FDA approval of ZYCUBO for Menkes disease, the sale of a Rare Pediatric Disease Priority Review Voucher by Cyprium Therapeutics, and strong financial performance in Q1 2026.

• Cyprium Therapeutics closed the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, with the transaction closing on March 30, 2026 [N1].
• Fortress Biotech’s Cyprium subsidiary announced plans to sell a $205 million Priority Review Voucher, with shares rising following the announcement [N3].
• The FDA approved ZYCUBO, the first and only approved treatment for Menkes disease in the United States, as announced in January 2026 [N8].
• Fortress Biotech reported net income of $137.2 million for Q1 2026, a significant increase from a net loss of $24.7 million in Q1 2025 [N2].
• The company’s shares rose following the announcement of the Priority Review Voucher sale by Cyprium [N4].

Fortress Biotech’s recent FDA approval of ZYCUBO for Menkes disease marks a significant regulatory milestone, establishing a commercial product in a rare disease area. The successful sale of a Rare Pediatric Disease Priority Review Voucher by Cyprium Therapeutics for $205 million demonstrates the company’s ability to monetize valuable regulatory assets. Strong liquidity and a sizable cash position provide financial flexibility to support ongoing development and commercialization activities. The company’s diversified portfolio of subsidiaries and strategic partnerships with established industry players position it to capitalize on multiple product opportunities across therapeutic areas.

Fortress Biotech faces risks related to its reliance on the successful development and commercialization of products by its subsidiaries, which are subject to regulatory, clinical, and market uncertainties. The company’s financial position is influenced by its ability to maintain compliance with debt covenants and to raise additional capital as needed. The paused dividends on Series A Preferred Stock have temporarily limited the company’s ability to access certain securities offerings. Operational risks include potential delays or failures in clinical development, competition, and the need to manage complex contractual obligations with licensors and third parties. Market acceptance of newly approved products and the ability to generate sustainable revenue remain challenges.

Fortress Biotech’s moat is derived from its diversified portfolio of subsidiaries and partner companies, each focused on distinct therapeutic areas and product candidates. The company’s expertise in navigating regulatory, scientific, and financial complexities provides a competitive advantage in advancing biopharmaceutical products. Strategic partnerships with industry leaders and the ability to leverage multiple financing and licensing arrangements enhance its operational flexibility. The company’s ownership stakes in publicly traded subsidiaries and its role in coordinating development and commercialization efforts create barriers to entry for competitors seeking similar breadth and depth. However, the biopharmaceutical industry’s inherent risks, including regulatory approvals and market acceptance, remain significant.

• Regulatory and Clinical Development Risks: The company’s subsidiaries face inherent risks in obtaining regulatory approvals and successfully completing clinical trials, which could delay or prevent commercialization of product candidates.
• Financing and Liquidity Risks: Fortress Biotech’s operations depend on maintaining sufficient liquidity and access to capital markets. Restrictions on securities offerings due to paused dividends on preferred stock and compliance with debt covenants pose risks to funding availability.
• Market and Commercialization Risks: The company’s ability to generate revenue depends on market acceptance of its products and successful commercialization by its subsidiaries, which may be affected by competition and pricing pressures.
• Operational and Contractual Risks: The company has numerous contractual obligations with licensors, CROs, CMOs, and other third parties. Failure to manage these obligations or unexpected costs could impact operations.

• Fortress Biotech, Inc. operates through multiple subsidiaries and partner companies focused on biopharmaceutical product development and commercialization, including Journey Medical Corporation, Mustang Bio, Avenue Therapeutics, Cellvation, Cyprium Therapeutics, Helocyte, Oncogenuity, and Urica Therapeutics.
• Checkpoint Therapeutics was a partner company until its acquisition by Sun Pharma in May 2025.
• The company leverages its expertise in business, scientific, regulatory, legal, and finance to support its subsidiaries and partners in achieving development and commercialization goals.
• Fortress Biotech's subsidiaries and partner companies engage in strategic arrangements such as joint ventures, partnerships, out-licensing, sales transactions, and public/private financings.
• The company’s revenue is primarily derived from its subsidiaries, with Journey Medical Corporation generating significant product revenue from dermatology products including Emrosi, Qbrexza, Accutane, and foam franchise products.
• Fortress Biotech reported total net revenue of approximately $63.3 million for the year ended December 31, 2025.
• The company’s consolidated net income was $110.4 million for the quarter ended March 31, 2026, compared to a net loss of $24.7 million for the same period in 2025, reflecting a significant positive change.
• Fortress Biotech had cash and cash equivalents of approximately $255.8 million as of March 31, 2026, with a current ratio of 2.86 and a cash ratio of 2.47, indicating strong liquidity.
• The company has a $50 million senior secured credit agreement with Oaktree, amended to extend maturity to June 30, 2028, with interest-only payments and financial covenants including minimum liquidity and net sales thresholds.
• Cyprium Therapeutics, a Fortress subsidiary, sold a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million, with 20% of proceeds payable to the NIH, and the transaction closed on March 30, 2026.
• Fortress Biotech announced FDA approval of ZYCUBO (copper histidinate), the first and only approved treatment for Menkes disease in the United States, in January 2026.
• The company has contractual obligations with licensors, CROs, CMOs, and other third parties for biopharmaceutical development, clinical trials, manufacturing, and commercialization services, generally terminable for convenience.
• Fortress Biotech’s subsidiaries have entered into license agreements with upfront and milestone payments totaling approximately $69.5 million and sales-based milestones totaling approximately $117.4 million.
• The company’s intangible assets primarily consist of product licenses with net book value of approximately $27.6 million as of December 31, 2025, amortized over 3 to 15 years.
• Fortress Biotech’s stockholders’ equity was approximately $62.2 million as of December 31, 2025, including non-controlling interests.
• The company’s operations have been financed primarily through equity and debt securities sales, proceeds from sales of subsidiaries, and warrant exercises.
• Fortress Biotech’s board paused dividends on Series A Preferred Stock in July 2024, affecting eligibility to use Form S-3 registration for securities offerings, with plans to regain eligibility upon filing the next Annual Report and paying accrued dividends.
• The company’s net cash provided by operating activities increased significantly in Q1 2026 compared to Q1 2025, driven by net income and changes in operating assets and liabilities.
• Fortress Biotech subleased its leased office space in New York starting March 15, 2026, expected to generate approximately $11.9 million in base rent over the sublease term ending August 31, 2031.